PMID- 24385268
OWN - NLM
STAT- MEDLINE
DCOM- 20150402
LR  - 20211021
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 46
IP  - 3
DP  - 2014 Aug
TI  - Combined biological therapy with lanreotide autogel and cabergoline in the 
      treatment of MEN-1-related insulinomas.
PG  - 678-81
LID - 10.1007/s12020-013-0145-2 [doi]
AB  - Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome associated 
      with the development of many endocrine tumors, involving mainly pituitary, 
      parathyroids, pancreas, although a proliferative state interests all 
      neuroendocrine system. MEN1 pancreatic neuroendocrine tumors (pNETs) are 
      multiples and can secrete different hormones. The therapeutic approach is based 
      on surgery which usually is followed by tumor relapse or persistence unless to be 
      highly aggressive. Biotherapy with somatostatin analogs and dopamine agonists 
      could be of great benefit to manage these patients without altering their life 
      quality. We report a case of a 36-year-old MEN1 man affected with multicentric 
      pNETs associated with insulinoma syndrome. Therapy with symptomatic agents 
      (diazoxide), as well as biotherapy (lanreotide, cabergoline) was started. At 
      6-month follow-up, symptomatic agents were stopped and disease control was only 
      based on lanreotide plus cabergoline. This combined biotherapy was able to 
      control endocrine syndromes and tumor growth. Subsequently, a safer and selective 
      surgical intervention on pNETs was performed. An excellent response to therapy 
      with lanreotide autogel and cabergoline has been observed in a MEN1 patient with 
      pNETs associated with insulinoma syndrome. The potential synergistic effects of 
      lanreotide autogel and cabergoline on insulin-secreting neuroendocrine tumors are 
      discussed.
FAU - Marciello, Francesca
AU  - Marciello F
AD  - Division of Endocrinology, Department of Clinical Medicine and Surgery, 
      University of Naples "Federico II", Naples, Italy, francesca.marciello@libero.it.
FAU - Di Somma, Carolina
AU  - Di Somma C
FAU - Del Prete, Michela
AU  - Del Prete M
FAU - Marotta, Vincenzo
AU  - Marotta V
FAU - Ramundo, Valeria
AU  - Ramundo V
FAU - Carratu, Annachiara
AU  - Carratu A
FAU - de Luca di Roseto, Chiara
AU  - de Luca di Roseto C
FAU - Camera, Luigi
AU  - Camera L
FAU - Colao, Annamaria
AU  - Colao A
FAU - Faggiano, Antongiulio
AU  - Faggiano A
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20140103
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ergolines)
RN  - 0 (Peptides, Cyclic)
RN  - 0G3DE8943Y (lanreotide)
RN  - 51110-01-1 (Somatostatin)
RN  - LL60K9J05T (Cabergoline)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Cabergoline
MH  - Drug Therapy, Combination
MH  - Ergolines/administration & dosage/*therapeutic use
MH  - Humans
MH  - Insulinoma/*drug therapy/pathology
MH  - Male
MH  - Multiple Endocrine Neoplasia Type 1/*drug therapy/pathology
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Peptides, Cyclic/administration & dosage/*therapeutic use
MH  - Somatostatin/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2014/01/05 06:00
MHDA- 2015/04/04 06:00
CRDT- 2014/01/04 06:00
PHST- 2013/09/03 00:00 [received]
PHST- 2013/12/04 00:00 [accepted]
PHST- 2014/01/04 06:00 [entrez]
PHST- 2014/01/05 06:00 [pubmed]
PHST- 2015/04/04 06:00 [medline]
AID - 10.1007/s12020-013-0145-2 [doi]
PST - ppublish
SO  - Endocrine. 2014 Aug;46(3):678-81. doi: 10.1007/s12020-013-0145-2. Epub 2014 Jan 
      3.